Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition

0575022 - ÚMG 2024 RIV US eng J - Journal Article
Cazzoli, G. - Romeo, F. - Pallavicini, A. - Peri, S. - Romanenghi, M. - Perez-Valencia, J. A. - Hagag, E. - Ferrucci, F. - Elgendy, Mohamed - Vittorioso, P. - Pece, S. - Foiani, M. - Westermarck, J. - Minucci, S.
Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition.
Cell Reports. Roč. 42, č. 6 (2023), č. článku 112616. ISSN 2211-1247. E-ISSN 2211-1247
R&D Projects: GA MŠMT LX22NPO5102; GA ČR(CZ) GJ19-22156Y
Institutional support: RVO:68378050
Keywords : oxidative phosphorylation * tumor cell * cancer therapy * regulator of CIP2A * PP2A inhibitor
OECD category: Oncology
Impact factor: 8.8, year: 2022
Method of publishing: Open access
https://www.sciencedirect.com/science/article/pii/S2211124723006277?via%3Dihub

Combined inhibition of oxidative phosphorylation (OXPHOS) and glycolysis has been shown to activate a PP2A-dependent signaling pathway, leading to tumor cell death. Here, we analyze highly selective mitochon-drial complex I or III inhibitors in vitro and in vivo to elucidate the molecular mechanisms leading to cell death following OXPHOS inhibition. We show that IACS-010759 treatment (complex I inhibitor) induces a reactive oxygen species (ROS)-dependent dissociation of CIP2A from PP2A, leading to its destabilization and degra-dation through chaperone-mediated autophagy. Mitochondrial complex III inhibition has analogous effects. We establish that activation of the PP2A holoenzyme containing B568 regulatory subunit selectively mediates tumor cell death, while the arrest in proliferation that is observed upon IACS-010759 treatment does not depend on the PP2A-B568 complex. These studies provide a molecular characterization of the events sub-sequent to the alteration of critical bioenergetic pathways and help to refine clinical studies aimed to exploit metabolic vulnerabilities of tumor cells.
Permanent Link: https://hdl.handle.net/11104/0346262